New globally faces of hepatitis B and C in the world

Gastroenterology and Hepatology from Bed to Bench

Volumn 4, Issue 4, 2011, Pages 171-174

  Alavian, Seyed Moayed ^a  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; BOCEPREVIR; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A; RIBAVIRIN; TELAPREVIR; VIRUS DNA;

CHRONIC HEPATITIS; DRUG RESISTANCE; EDITORIAL; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; IRAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NONHUMAN; RISK FACTOR; SIDE EFFECT; VERTICAL TRANSMISSION; VIREMIA; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 80053408341     PISSN: 20082258     EISSN: 20084234     Source Type: Journal    
DOI: None     Document Type: Editorial

References (25)

1. Zali MR, Mohaghegh Shalmani H. The changing epidemiology of hepatitis B in Iran. Gastroenterol Hepatol Bed Bench 2010; 3:1-4.
2. Webster DP, Klenerman P, Collier J, Jeffery KJ. Development of novel treatments for hepatitis C. Lancet Infect Dis 2009; 9: 108-17.
3. Marcellin P. Hepatitis B and hepatitis C in 2009. Liver Int 2009; 29: S1-8.
4. Alavian SM. Hepatitis B virus infection in Iran; changing the epidemiology. Iran J Clin Infect Dis 2010; 5:51-61.
5. Nokhodian Z, Kassaian N, Ataei B, Javadi AA, Shoaei P, Farajzadegan Z, et al. Hepatitis B Markers in Isfahan, Central Iran: A Population-Based Study. Hepat Mon 2009; 9:12-16.
6. Alavi-Moghaddam M, Alavian SM, Hajibeigi B. Preliminary report on safety and response rate of pegylated interferon-alpha 2 a (pegasys) in genotype D chronic hepatitis B patients in Iran. Gastroenterol Hepatol Bed Bench 2010; 3:98-104.
7. Ferreira PR, Tenore Sde B. Response predictors to treatment with pegylated interferon in chronic hepatitis B. Braz J Infect Dis 2010; 14:519-25.
8. Agdamag DM, Kageyama S, Leano PS, Solante RM, Telan EF, Que ER, et al. Prediction of response to treatment of chronic hepatitis B with pegylated interferon in the Philippines. J Med Virol 2010; 82:213-19.
9. Ravanshad M, Sabahi F, Falahi S, Kenarkoohi A, Amini-Bavil-Olaee S, Hosseini SY, et al. Prediction of hepatitis B virus lamivudine resistance based on YMDD. Hepat Med 2011; 11:108-13.
10. Sayan M. Molecular Diagnosis of Entecavir Resistance. Hepat Mon 2010; 10:42-47.
11. Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44:675-84.
12. Alavian SM, Gholami B, Masarrat S. Hepatitis C risk factors in Iranian volunteer blood donors: A casecontrol study. J Gastroenterol Hepatol 2002; 17:1092-97.
13. Alavian SM, Kabir A, Ahmadi AB, Lankarani KB, Shahbabaie MA, Ahmadzad-Asl M. Hepatitis C infection in hemodialysis patients in Iran: A systematic review. Hemodial Int 2010; 14:253-62.
14. Alavian SM, Tabatabaei SV, Lankarani KB. Epidemiology of HCV Infection among Thalassemia Patients in eastern Mediterranean Countries: a Quantitative Review of Literature. Iran Red Cres Med J 2010; 12:365-76.
15. Wyles DL. Moving beyond interferon alfa: investigational drugs for hepatitis C virus infection. Top HIV Med. 2010; 18:132-36.
16. Alavian SM. Hepatitis C virus infection: Epidemiology, risk factors and prevention strategies in public health in I.R. IRAN. Gastroenterol Hepatol Bed Bench 2010; 3:5-14.
17. Jia WD, Zhang CH. Interferon: A Sharp Sword to Overcome HCV or HBV-Related Liver Diseases? Hepat Mon 2010; 10:237-38.
18. De Re V. Interferon-Based Therapy for Chronic Hepatitis C: Current and Future Perspectives. Hepat Mon 2010; 10:231-32.
19. Gevers TJ, Slavenburg S, van Oijen MG, Drenth JP. Treatment extension benefits HCV genotype 1 patients without rapid virological response: a systematic review. Neth J Med 2011; 69:216-21.
20. Oze T, Hiramatsu N, Yakushijin T, Mochizuki K, Imanaka K, Yamada A, et al. The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan. J Gastroenterol 2011; 46:944-52.
21. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139:120-29.
22. Background Material for Boceprevir Advisory Committee Division of Antiviral Products (DAVP) April 27, 2011. Available from:http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/drugs/AntiviralDrugsAd visoryCommittee/ucm252341.pdf. [Accessed at: July 2011]
23. Giannini EG, Basso M, Savarino V, Picciotto A. Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients. Aliment Pharmacol Ther 2010; 31:502-508.
24. Swain M, Shiffman ML. Durability of sustained virological response (SVR) after treatment with peginterferon alfa-2a (40KD) (PEGASYS®) alone or a combination with RIBAVIRIN (COPEGUS): result of an ongoing long-term follow up study. Hepatology 2004; 40:400-401.
25. Pradat P, Tillmann HL, Sauleda S, Braconier JH, Saracco G, Thursz M, et al. Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications. J Viral Hepat 2007; 14:556-63.